12/6
08:11 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Low
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
12/6
08:00 am
urgn
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/5
03:33 pm
urgn
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® [Yahoo! Finance]
Low
Report
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® [Yahoo! Finance]
12/5
03:30 pm
urgn
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Low
Report
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
12/5
03:15 pm
urgn
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
Low
Report
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
12/2
07:59 pm
urgn
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade [Yahoo! Finance]
Medium
Report
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade [Yahoo! Finance]
12/2
08:19 am
urgn
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs [Yahoo! Finance]
Low
Report
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs [Yahoo! Finance]
12/2
08:00 am
urgn
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
Low
Report
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
11/28
12:23 pm
urgn
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment [Yahoo! Finance]
Low
Report
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment [Yahoo! Finance]
11/26
08:06 am
urgn
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® [Yahoo! Finance]
Neutral
Report
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® [Yahoo! Finance]
11/26
08:00 am
urgn
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Low
Report
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
11/9
09:50 am
urgn
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target [Yahoo! Finance]
Medium
Report
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target [Yahoo! Finance]
11/7
02:31 am
urgn
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
11/6
11:24 am
urgn
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/6
08:00 am
urgn
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
Medium
Report
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
11/5
08:00 am
urgn
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
Low
Report
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
10/30
08:00 am
urgn
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
Medium
Report
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
10/28
08:00 am
urgn
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
Medium
Report
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
10/19
11:01 am
urgn
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years [Yahoo! Finance]
Medium
Report
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years [Yahoo! Finance]
10/16
09:40 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $40.00 price target on the stock.
Medium
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $40.00 price target on the stock.
10/15
04:46 pm
urgn
UroGen Pharma announces FDA acceptance of new drug application for UGN-102 [Seeking Alpha]
Low
Report
UroGen Pharma announces FDA acceptance of new drug application for UGN-102 [Seeking Alpha]
10/15
04:30 pm
urgn
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
Low
Report
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
10/15
08:47 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
10/15
07:51 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
UroGen Pharma Ltd. (NASDAQ: URGN) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
10/9
08:12 am
urgn
UroGen Pharma names Chris Degnan as CFO [Seeking Alpha]
Low
Report
UroGen Pharma names Chris Degnan as CFO [Seeking Alpha]